Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PRECIGEN, INC. (PGEN)

Precigen Q3 2026 revenue rises to $74.1 million; net income $35.8 million

Positive Impact 3 of 5 earnings Written later

Precigen reported third quarter 2026 results for the period ended September 30, 2026. Total revenues were $74.1 million, up $71.2 million from a year earlier, mainly from commercial sales of PAPZIMEOS after its August 2025 FDA approval, and the company posted net income of $35.8 million, or $0.08 per diluted share, compared with a net loss attributable to common shareholders of $325.3 million in the prior-year quarter. Operating cash flow was positive at $11.9 million, a full quarter ahead of the company's guidance.

Key points

  • Total revenues $74.1 million versus $2.9 million a year earlier; PAPZIMEOS net product revenue was $72.9 million, up 37% from the prior quarter.
  • Net income $35.8 million, or $0.08 per diluted share, versus a prior-year net loss attributable to common shareholders of $325.3 million that included a $111.5 million warrant liability charge and a $179.0 million deemed dividend.
  • Net cash provided by operating activities was $11.9 million in the third quarter, which the company said was a full quarter ahead of its guidance.
  • Cash, cash equivalents and investments totaled $51.0 million as of September 30, 2026.

The filing

CompanyPRECIGEN, INC. (PGEN)
Form8-K, current report
Filed with the SECNov 4, 2026, 7:40 PM ET
Accession number0000950103-26-016970

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.